A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the
maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral
vorinostat in patients with malignant lymphoma.